Engineering of A3 adenosine and P2Y nucleotide receptors and their ligands

Modification of the ribose moiety of nucleotides and nucleosides has provided new insights into structural and conformational requirements for ligands at P2Y nucleotide receptors and at adenosine receptors (ARs). Methanocarba derivatives (containing a rigid bicyclic ring system in place of ribose) of adenosine, ATP, ADP, UTP, UDP, and other receptor agonist analogs were synthesized. Biological evaluation led to the conclusion that in general the Northern (N)‐conformation was favored over the Southern (S)‐conformation of the pseudoribose moiety at A1 and A3 ARs and at P2Y1, P2Y2, P2Y4, or P2Y11 receptors, but not P2Y6 receptors. At the hA3 AR a new full agonist, MRS1898, the (N)‐methanocarba equivalent of Cl‐IB‐MECA (2‐chloro‐N6‐(3‐iodobenzyl)‐5'‐N‐methylcarbamoyladenosine), had a Ki value of 1.9 nM in binding to the hA3 AR expressed in CHO cells. Functional assays confirmed the selectivity of MRS1898, although Cl‐IB‐MECA was even more functionally selective for human A3 vs. hA1 and hA2A ARs. Thirty µM MRS1898 did not induce apoptosis in HL‐60 cells, suggesting that some of the proapoptotic effects of Cl‐IB‐MECA may be nonreceptor‐mediated. Manipulation of the sequence of A3 ARs through site‐directed mutagenesis has led to pharmacologically unique constructs: constitutively active receptors and “neoceptors.” Such engineered receptors may later prove to have potential for cardioprotection through gene transfer. Effects of single amino acid replacement were interpreted using a rhodopsin‐based model of ligand‐A3 receptor interactions, leading to the proposal that a movement of the conserved W243 in TM6 may be involved in AR activation. Drug Dev. Res. 58:330–339, 2003. © 2003 Wiley‐Liss, Inc.